Postscript re ABBV/ENTA’s global 3-DAA program: The MALACHITE-1 and -2 phase-4 trials listed in #msg-94927196, which would have tested ABBV/ENTA’s 3-DAA regimen vs Incivek + PEG/RBV, are now obsolete and won’t be conducted.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”